Putnam Investments’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Putnam Investments’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,106	Closed	-$388K	–	1234
2023 Q1	$388K	Buy	+16,106	New	+$202K	﹤0.01%	996
2021 Q2	–	Sell	-211,006	Closed	-$2.21M	–	852
2021 Q1	$2.21M	Buy	211,006 +63,579	+43%	+$895K	﹤0.01%	664
2020 Q4	$2.5M	Buy	147,427 +1,251	+0.9%	+$18.8K	﹤0.01%	634
2020 Q3	$1.88M	Buy	146,176 +9,288	+7%	+$117K	﹤0.01%	674
2020 Q2	$1.93M	Buy	+136,888	New	+$1.73M	﹤0.01%	685

Other funds holding PRVB

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Putnam Investments's PRVB Position: Q2 2023 in Review

Putnam Investments sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 16,106 shares — an estimated $388K sold.

Putnam Investments first reported a position in PRVB in Q2 2020 and held it in 5 quarters. The position peaked at $2.5M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Putnam Investments reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Putnam Investments sold 16,106 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $388K.
Putnam Investments first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Putnam Investments's Provention Bio, Inc. Common Stock position peaked at $2.5M in Q4 2020.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Putnam Investments's 13F filing for Q2 2023, filed 14 Aug 2023.